Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF5) and pentafluoroethyl (C2F5) substituents: Improved antiproliferative agents against prostate cancer.

Pertusati F, Ferla S, Bassetto M, Brancale A, Khandil S, Westwell AD, McGuigan C.

Eur J Med Chem. 2019 Jul 3;180:1-14. doi: 10.1016/j.ejmech.2019.07.001. [Epub ahead of print]

PMID:
31288149
2.

TiO2 Photocatalyzed Oxidation of Drugs Studied by Laser Ablation Electrospray Ionization Mass Spectrometry.

van Geenen FAMG, Franssen MCR, Miikkulainen V, Ritala M, Zuilhof H, Kostiainen R, Nielen MWF.

J Am Soc Mass Spectrom. 2019 Apr;30(4):639-646. doi: 10.1007/s13361-018-2120-x. Epub 2019 Jan 7.

3.

Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.

Advani SM, Advani PG, VonVille HM, Jafri SH.

BMC Cancer. 2018 Nov 27;18(1):1174. doi: 10.1186/s12885-018-5080-4.

4.

The relationship between muscle mass and function in cancer cachexia: smoke and mirrors?

Ramage MI, Skipworth RJE.

Curr Opin Support Palliat Care. 2018 Dec;12(4):439-444. doi: 10.1097/SPC.0000000000000381.

PMID:
30138131
5.

Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy.

Kinsey E, Ajazi E, Wang X, Johnston MAM, Crawford J.

J Thorac Oncol. 2018 Sep;13(9):1294-1301. doi: 10.1016/j.jtho.2018.05.029. Epub 2018 Jul 4.

PMID:
29981438
6.

Novel Trifluoromethylated Enobosarm Analogues with Potent Antiandrogenic Activity In Vitro and Tissue Selectivity In Vivo.

Dart DA, Kandil S, Tommasini-Ghelfi S, Serrano de Almeida G, Bevan CL, Jiang W, Westwell AD.

Mol Cancer Ther. 2018 Sep;17(9):1846-1858. doi: 10.1158/1535-7163.MCT-18-0037. Epub 2018 Jun 12.

7.

Evaluation of ostarine as a selective androgen receptor modulator in a rat model of postmenopausal osteoporosis.

Hoffmann DB, Komrakova M, Pflug S, von Oertzen M, Saul D, Weiser L, Walde TA, Wassmann M, Schilling AF, Lehmann W, Sehmisch S.

J Bone Miner Metab. 2019 Mar;37(2):243-255. doi: 10.1007/s00774-018-0929-9. Epub 2018 May 21.

PMID:
29785666
8.

Silver linings on the horizon: highlights from the 10th Cachexia Conference.

Ebner N, von Haehling S.

J Cachexia Sarcopenia Muscle. 2018 Feb;9(1):176-182. doi: 10.1002/jcsm.12290.

9.

Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models.

Morimoto M, Aikawa K, Hara T, Yamaoka M.

Oncol Lett. 2017 Dec;14(6):8066-8071. doi: 10.3892/ol.2017.7200. Epub 2017 Oct 17.

10.

Structural elucidation of major selective androgen receptor modulator (SARM) metabolites for doping control.

Garg N, Hansson A, Knych HK, Stanley SD, Thevis M, Bondesson U, Hedeland M, Globisch D.

Org Biomol Chem. 2018 Jan 31;16(5):698-702. doi: 10.1039/c7ob03030d.

PMID:
29319101
11.

Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet.

Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D.

JAMA. 2017 Nov 28;318(20):2004-2010. doi: 10.1001/jama.2017.17069. Erratum in: JAMA. 2018 Feb 20;319(7):724.

12.

Overcoming obstacles in the design of cancer anorexia/weight loss trials.

Le-Rademacher JG, Crawford J, Evans WJ, Jatoi A.

Crit Rev Oncol Hematol. 2017 Sep;117:30-37. doi: 10.1016/j.critrevonc.2017.06.008. Epub 2017 Jun 24. Review.

13.

Detection of SARMs in doping control analysis.

Thevis M, Schänzer W.

Mol Cell Endocrinol. 2018 Mar 15;464:34-45. doi: 10.1016/j.mce.2017.01.040. Epub 2017 Jan 27. Review.

PMID:
28137616
14.

Analytical strategies to detect enobosarm administration in bovines.

Cesbron N, Sydor A, Penot M, Prevost S, Le Bizec B, Dervilly-Pinel G.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2017 Apr;34(4):632-640. doi: 10.1080/19440049.2016.1258122. Epub 2016 Nov 28.

PMID:
27827563
15.

Tissue Selective Androgen Receptor Modulators (SARMs) Increase Pelvic Floor Muscle Mass in Ovariectomized Mice.

Ponnusamy S, Sullivan RD, Thiyagarajan T, Tillmann H, Getzenberg RH, Narayanan R.

J Cell Biochem. 2017 Mar;118(3):640-646. doi: 10.1002/jcb.25751. Epub 2016 Nov 28.

PMID:
27681158
16.

Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.

Hu DG, Selth LA, Tarulli GA, Meech R, Wijayakumara D, Chanawong A, Russell R, Caldas C, Robinson JL, Carroll JS, Tilley WD, Mackenzie PI, Hickey TE.

Cancer Res. 2016 Oct 1;76(19):5881-5893. Epub 2016 Aug 5.

17.

Novel therapeutic options for cachexia and sarcopenia.

Molfino A, Amabile MI, Rossi Fanelli F, Muscaritoli M.

Expert Opin Biol Ther. 2016 Oct;16(10):1239-44. doi: 10.1080/14712598.2016.1208168. Epub 2016 Jul 11. Review.

PMID:
27382931
18.

Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).

Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, Dalton JT.

Curr Oncol Rep. 2016 Jun;18(6):37. doi: 10.1007/s11912-016-0522-0. Review.

19.

Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.

Coss CC, Jones A, Dalton JT.

Invest New Drugs. 2016 Aug;34(4):458-67. doi: 10.1007/s10637-016-0353-8. Epub 2016 Apr 22.

PMID:
27105861
20.

Specific characterization of non-steroidal selective androgen peceptor modulators using supercritical fluid chromatography coupled to ion-mobility mass spectrometry: application to the detection of enobosarm in bovine urine.

Beucher L, Dervilly-Pinel G, Cesbron N, Penot M, Gicquiau A, Monteau F, Le Bizec B.

Drug Test Anal. 2017 Feb;9(2):179-187. doi: 10.1002/dta.1951. Epub 2016 Mar 16.

PMID:
26990774

Supplemental Content

Loading ...
Support Center